Antineoplastic-Immunotherapy Virus-Based Agents

"Antineoplastic-Immunotherapy Virus-Based Agents" is a formulary and compendial therapeutic classification rather than a formal regulatory designation, established to categorize oncolytic viral therapies

"Antineoplastic-Immunotherapy Virus-Based Agents" is a formulary and compendial therapeutic classification rather than a formal regulatory designation, established to categorize oncolytic viral therapies Agents in this class—such as talimogene laherparepvec—are genetically modified, replication-competent viruses engineered to selectively replicate within cancer cells to cause targeted oncolysis while simultaneously releasing tumor-associated antigens and immunostimulatory cytokines Clinically, t...

Agents in this class—such as talimogene laherparepvec—are genetically modified, replication-competent viruses engineered to selectively replicate within cancer cells to cause targeted oncolysis while simultaneously releasing tumor-associated antigens and immunostimulatory cytokines This dual mechanism mediates direct tumor destruction and stimulates an innate and adaptive antitumor immune response

This dual mechanism mediates direct tumor destruction and stimulates an innate and adaptive antitumor immune response

Clinically, these agents are primarily indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma